CytoDyn Appoints Seenu Srinivasan, Ph.D. as Executive Director of CMC Regulatory Affairs
August 26, 2021 17:02 ET
|
CytoDyn Inc.
Dr. Srinivasan provides 30 years of broad regulatory and drug development experience including a career serving as Director of CMC Regulatory Affairs for Regeneron Pharmaceuticals, Inc. where he led...
CytoDyn’s Final mTNBC Report Indicates as Much as 980% Increase in 12-Month Overall Survival and Up to 660% in 12-Month Modified Progression Free Survival
August 25, 2021 08:00 ET
|
CytoDyn Inc.
Decreases in Circulating Tumor Cells after leronlimab induction were seen in 73% of the patients and associated with increase in PFS and OS CytoDyn plans to update its Breakthrough Therapy...
CytoDyn Receives FDA Guidance for its HIV BLA Dose Justification Report
August 13, 2021 06:00 ET
|
CytoDyn Inc.
Company Believes All Issues Are Addressable and it Will Be Able to Continue BLA Resubmission CMC and Non-Clinical Sections Will Be Fully Resubmitted as Early as September 2021 VANCOUVER,...
CytoDyn to Hold Webcast on July 22 to Discuss Results from Cancer Trials, HIV BLA Status, NASH, and COVID-19 Trials
July 19, 2021 16:41 ET
|
CytoDyn Inc.
VANCOUVER, Washington, July 19, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with...
CytoDyn Announces Preliminary Results from 30 mTNBC Patients Treated with Leronlimab. Decreases in CAMLs after 4 Doses of Leronlimab were Identified in Over 70% of Patients and were Associated with a 450% Significant Increase in Overall Survival at 12-Month Analysis
July 19, 2021 06:00 ET
|
CytoDyn Inc.
VANCOUVER, Washington, July 19, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the...
CytoDyn’s Trial for Metastatic Triple-Negative Breast Cancer Demonstrates Safety with 350 mg, 525 mg and 700 mg Dosages; Officially Advances to Phase 2 from Phase 1b
July 12, 2021 06:00 ET
|
CytoDyn Inc.
CytoDyn anticipates preliminary efficacy data regarding potential responders in metastatic triple-negative breast cancer in approximately two weeks VANCOUVER, Washington, July 12, 2021 (GLOBE...
CytoDyn Granted a Significant Patent by USPTO for Methods of Treating Coronavirus Infection with Leronlimab
July 06, 2021 06:00 ET
|
CytoDyn Inc.
VANCOUVER, Washington, July 06, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY), ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with...
CytoDyn Submits Dose Justification Report to FDA to Begin Overcoming Deficiencies in its BLA for HIV
July 01, 2021 18:07 ET
|
CytoDyn Inc.
Management works to advance its BLA filing seeking FDA approval for leronlimab as a combination therapy for HIV patients while continuing its evaluation of other potential indications VANCOUVER,...
CytoDyn Inc. Announces Positive Preliminary Results of Unblinded Data from Long-Haulers Trial Showing Greater Improvement in Leronlimab Group over Placebo in 18 of 24 Symptoms
June 21, 2021 08:30 ET
|
CytoDyn Inc.
VANCOUVER, Washington, June 21, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY), ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with...
CytoDyn to Hold Webcast on June 21 to Discuss Unblinded Data from COVID-19 Long-Haulers Trial and Other Developments
June 16, 2021 16:01 ET
|
CytoDyn Inc.
VANCOUVER, Washington, June 16, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with...